Articles tagged with Clinical Trials
A new study suggests that supplementing with BCAAs alongside an exercise program may help reduce fatigue, improve strength, and ease symptoms of depression for older adults. The research found notable improvements in participants who combined a BCAA supplement with an eight-week exercise program.
The Lundquist Institute has been awarded $9 million by the California Institute for Regenerative Medicine (CIRM) to establish a Community Center of Excellence for Regenerative Medicine. This center will expand access to cutting-edge regenerative therapies and create skilled healthcare professionals in underserved communities.
The study highlights the frequent use of aerosol therapy in critically ill patients with acute respiratory distress syndrome (ARDS), with bronchodilators being the most commonly prescribed drugs. However, the lack of sound scientific evidence and randomized controlled trials suggests that standardized protocols are needed to align clin...
A randomized clinical trial found that an unsupervised online Tai Chi intervention improved knee pain and function compared to the control group at 12 weeks. This free web-based intervention offers a safe, accessible, and scalable option for guideline-recommended osteoarthritis exercise.
A new study may transform the diagnosis of Britain's number one cancer, lung cancer. Researchers are investigating whether low-dose CT scans can detect lung cancers earlier than current chest X-rays. The study aims to identify which patients would benefit from these more accurate scans.
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
The termination of thousands of federal grants has raised ethical concerns about clinical trial closures, particularly among children and adolescents. Researchers argue that sudden stops can break trust and harm participants, violating long-standing principles.
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
A recent study published in CANCER found that the number and complexity of cancer clinical trials have varied greatly across low- and middle-income countries (LMICs) since 2001. While economic growth has been a contributing factor, it is not the sole determinant of cancer clinical trial growth among LMICs.
A randomized clinical trial found that colchicine did not improve functional capacity or inflammatory markers in adults with long COVID. Researchers highlight the need for new therapeutic strategies for this condition.
A randomized clinical trial showed that DMEK graft success is comparable between diabetes-positive and non-diabetes donor corneas after 1 year. The study's findings support the use of diabetes-positive donor corneas for endothelial keratoplasty procedures.
Large language models could streamline clinical trial processes by refining eligibility criteria and tailoring informed consent materials. They also show potential for faster, more accurate patient screening and real-time safety monitoring.
UCSF researchers found a key cellular switch driving pulmonary fibrosis and developed a new therapy to block it in mice. The treatment works by preventing healthy lung cells from converting to harmful cell types, reducing scarring and improving lung function.
The ISSCR 2026 Annual Meeting will bring together academic and industry leaders to explore advances in stem cell science and regenerative medicine. Scientists can submit abstracts by February 25, 2026, for oral presentations and Travel and Merit Awards.
A landmark study published in the New England Journal of Medicine reports the long-term safety and efficacy of gene therapy for children with ADA-SCID, a rare immune disorder. The treatment resulted in a 100% survival rate and over 95% cure rate, with patients able to respond to routine childhood vaccinations.
Boston Children's Hospital has received a $35 million donation from Hansjoerg Wyss to further its translational neuroscience research, focusing on rare brain disorders and intellectual disability. The gift will support clinical trials, fellowships, and pilot studies, aiming to develop new therapies for vulnerable children.
In a multicenter randomized clinical trial, rapid induction of injectable extended-release buprenorphine showed higher retention rates compared to standard induction. Administration of injection 2 after 1 week was well tolerated and reduced time below target therapeutic levels.
A recent study published in JAMA challenges the common practice of individualizing blood pressure targets based on preoperative nighttime mean arterial pressure. The findings suggest that this approach may not be effective for high-risk patients undergoing major abdominal surgery.
A new global standard has been established to harmonize outcomes measurement in dengue treatment trials, addressing a longstanding discrepancy that limits the comparison of evidence. The initiative aims to accelerate the development of treatments for dengue fever and improve clinical guidelines, with input from experts worldwide.
The new centre supports multiple clinical trials in parallel, enabling comprehensive evaluations of organ health across physiological systems. It also provides hands-on training opportunities for healthcare professionals, bridging the gap between theoretical knowledge and practical application.
Researchers have developed an innovative approach combining serial brain biopsies with multi-omics analyses to uncover dynamic changes in recurrent glioblastoma tumors. This breakthrough study reveals that CAN-3110 triggered powerful immune responses deep inside the tumor, which were invisible to standard imaging.
Researchers tested a user-carried safety device that prolongs survival under snow and gains valuable time for rescue operations. The study found that the device can sustain a buried person with patent airways for over 35 minutes.
An open-label placebo treatment was associated with improved quality of life and reduced pain-related disability in patients with migraine. However, the treatment did not reduce headache frequency in this study.
Researchers found that 27% of breast cancer cases have genetic features guiding personalized treatment immediately. The study identified over 8,300 cases suitable for future research, providing insights into prognosis and potential new treatments.
The Keck School of Medicine has been recognized for its commitment to partnering with local communities in Los Angeles to address their critical needs through outreach, education, and service. The institution's community agenda is defined in collaboration with the communities it serves.
This randomized clinical trial shows electroacupuncture significantly accelerates postprostatectomy urinary continence recovery. It may serve as a safe adjunct to standard care, supporting its integration into multimodal rehabilitation protocols.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new clinical trial found that patients with mild-to-moderate knee osteoarthritis reported significant reductions in pain and improved physical function after receiving low-dose radiation therapy. The study showed a 70% response rate in the high-dose group, compared to 42% in the placebo group.
A large-scale study revealed that SEEG improves decision-making in temporal lobe epilepsy by identifying specific patterns like LFPS that predict better outcomes. This enhancement enables clinicians to make more precise surgical plans, particularly for patients with non-concordant imaging or suspected bilateral epilepsy.
A large prospective volumetric study evaluates the immediate and long-term effects of hyaluronic acid (HA) fillers on facial volume and patient-reported outcomes. The study showed significant improvements in facial appearance and quality of life, with volume maintenance varying by age, smoking history, and body mass index.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
Researchers have designed a novel quintuple agonist combining GLP-1R, GIPR, and PPAR agonism to treat obesity and type 2 diabetes. The molecule, lanifibranor, shows potent effects in reducing body weight and improving hyperglycaemia in mice with obesity and insulin resistance.
Researchers are testing whether low-concentrate atropine drops can delay the onset of myopia in children. The study aims to reduce the risk of sight-threatening complications later in life by decreasing how nearsighted someone becomes.
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
A daily pill of baricitinib, a Janus kinase inhibitor, preserves insulin-producing beta cell function and slows type 1 diabetes progression in people recently diagnosed with the condition. The treatment's therapeutic effect is lost when it's stopped, justifying its testing in earlier stages to prevent or delay clinical diagnosis.
Researchers are conducting a national study to test the effectiveness of daily atropine drops in delaying and reducing nearsightedness in young children. The study aims to enroll over 600 children aged 6-11 who will receive either atropine or a placebo, with results comparing the timing of onset and progression of myopia.
The Ver-A-T1D trial suggests that verapamil could preserve beta-cell function in adults with newly diagnosed type 1 diabetes. The study demonstrated encouraging trends towards beta-cell preservation and well-established safety profile, but narrowly missed statistical significance.
A new trial has shown that a lower dose of the immunomodulatory drug ATG is safe and effective in preventing the progression of type 1 diabetes in young people. The study found that the drug was able to arrest or delay the progression of T1D at a dose as low as 0.5mg/kg, with a good safety profile.
Stem cell transplantation has been shown to reverse stroke damage in mice by regenerating neurons and restoring motor functions. The treatment also improved blood-brain barrier integrity, reduced inflammation, and promoted new blood vessel formation.
A phase 3 trial of once-daily orforglipron found substantial weight loss in people with obesity but not type 2 diabetes. The medication improved cardiometabolic levels and was associated with significant reductions in body weight, waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol.
A randomized trial shows that implanting a brain shunt in older patients with normal pressure hydrocephalus significantly improves symptoms, including gait speed, cognition, and bladder control. The study resolves controversy surrounding the condition's existence and treatment effectiveness.
Home high-intensity aerobic training outperforms home balance training in improving ataxia symptoms, fatigue, and aerobic fitness among those with cerebellar ataxias. Regular training maintained benefits at 1 year.
Two large-scale clinical trials found that a higher dose of semaglutide significantly improves weight loss and related health outcomes in adults with obesity. The study revealed an average weight loss of nearly 19% in those receiving the higher dose, compared to 10% with the standard dose or placebo.
A randomized clinical trial found that acupuncture provided greater improvements in back pain-related disability compared to usual medical care alone. The study suggests that acupuncture needling is an effective and safe treatment option for older adults with chronic low back pain.
A 12-week high-intensity interval training intervention did not improve hippocampal integrity or cognitive/mental health impairments, but reduced cannabis craving. Regular physical exercise may be a potential strategy for managing cannabis use disorder.
DZ-002 is an innovative cancer treatment developed through a collaborative effort among Georgia State University, Emory University and Cedars-Sinai Medical Center. The technology harnesses targeted radiation to destroy tumors with precision, offering hope for improved patient outcomes.
The new model simplifies trial openings and streamlines patient enrollment, enabling rapid expansion across multiple locations. City of Hope operates a single centralized hub with diverse research locations, reducing patient enrollment times and increasing access to leading-edge treatment options.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
Researchers found that individuals from African American, Hispanic and Asian groups were less likely to have elevated amyloid in the brain based on blood levels of p-tau217. This finding suggests that these groups may have a lower prevalence of amyloid and are not at sufficient risk to qualify for amyloid-lowering trials.
A single dose of MM120 (lysergide) produced a dose-dependent reduction in anxiety in participants with moderate to severe generalized anxiety disorder. The study supports the efficacy of MM120 and informs dose selection for phase 3 pivotal trials.
Systematic review highlights the challenges of nonregistration, premature discontinuation, and nonpublication of randomized clinical trials, affecting non-industry-sponsored trials. Funders' requirements and ethics committee oversight can mitigate these issues.
The TARGET statement aims to improve reporting transparency and peer review in observational studies, enabling better interpretation and application of results. By following the guideline recommendations, researchers can provide more reliable information for clinicians and readers.